Indication · mild-to-moderate alzheimer's disease

mild-to-moderate alzheimer's disease FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 2 mild-to-moderate alzheimer's disease drugs. 1 FDA approval recorded, most recently ZUNVEYL (benzgalantamine) on July 29, 2024.

Drugs

DrugSponsorModalityDesignations
ZUNVEYL (benzgalantamine)ACOG——
simufilam (PTI-125)FLNA——

Upcoming catalysts

No events in this view.

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
March 25, 2025simufilam (PTI-125)FLNATopline readoutmild-to-moderate Alzheimer's diseaseMissed primary endpointSEC Form 8-K
July 29, 2024ZUNVEYL (benzgalantamine)ACOGFDA approvalmild-to-moderate Alzheimer's diseaseApprovedsec_s1

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 2 and 2.

Questions

What mild-to-moderate alzheimer's disease drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.